--- title: "BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $11,701.66 in Stock" description: "BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 521 shares at $22.46 each, totaling $11,701.66. Post-sale, he holds 308,486 shares valued at approximately $6.93 million, marking a 0.17% d" type: "news" locale: "en" url: "https://longbridge.com/en/news/242695227.md" published_at: "2025-06-01T00:30:43.000Z" --- # BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $11,701.66 in Stock > BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 521 shares at $22.46 each, totaling $11,701.66. Post-sale, he holds 308,486 shares valued at approximately $6.93 million, marking a 0.17% decrease in ownership. The stock recently traded down 2.2% to $21.83. BioLife reported $0.04 EPS for the last quarter, exceeding estimates, with revenue of $23.94 million. Analysts have a consensus rating of "Moderate Buy" with an average price target of $31.17. Institutional investors own 93.24% of the stock. BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 521 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $22.46, for a total transaction of $11,701.66. Following the transaction, the executive vice president now directly owns 308,486 shares in the company, valued at $6,928,595.56. The trade was a 0.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Get **BioLife Solutions** alerts: ## BioLife Solutions Trading Down 2.2% - Best Biotech Stocks to Invest in Now BLFS stock traded down $0.49 on Friday, reaching $21.83. The company's stock had a trading volume of 786,262 shares, compared to its average volume of 389,140. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market cap of $1.04 billion, a PE ratio of -20.59 and a beta of 2.01. The business has a fifty day simple moving average of $22.94 and a two-hundred day simple moving average of $25.09. BioLife Solutions, Inc. has a 12-month low of $18.70 and a 12-month high of $29.55. BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The firm had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. As a group, research analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year. ## Institutional Trading of BioLife Solutions - 3 Small-Cap Medical Stocks Moving Markets Today Several hedge funds and other institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. acquired a new stake in shares of BioLife Solutions in the first quarter worth approximately $30,789,000. Raymond James Financial Inc. acquired a new position in shares of BioLife Solutions during the 4th quarter worth about $20,664,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at about $19,805,000. Royal Bank of Canada raised its stake in BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider's stock valued at $15,948,000 after acquiring an additional 617,320 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of BioLife Solutions during the 4th quarter worth approximately $11,113,000. 93.24% of the stock is owned by institutional investors and hedge funds. ## Wall Street Analyst Weigh In BLFS has been the topic of several research reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a report on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $31.17. **Read Our Latest Report on BioLife Solutions** ## BioLife Solutions Company Profile (Get Free Report) BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. ## Read More - Five stocks we like better than BioLife Solutions - The How And Why of Investing in Oil Stocks - Nike’s Amazon Expansion Could Signal a Turnaround in 2025 - 3 Tickers Leading a Meme Stock Revival - Intel’s Turnaround May Be the Best Bet No One’s Watching - What Are Dividends? Buy the Best Dividend Stocks - 3 Defense Stocks That Will Profit From a Golden Dome *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in BioLife Solutions Right Now? Before you consider BioLife Solutions, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list. While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [BLFS.US - BioLife Solutions](https://longbridge.com/en/quote/BLFS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | BioLife Solutions｜8-K：2025 财年 Q4 营收 24.8 百万美元超过预期 | | [Link](https://longbridge.com/en/news/272274247.md) | | 每千次展示 60 美元！OpenAI 用高价拉开 “AI 广告” 大幕 | 为应对 AI 巨额开支，OpenAI 正式测试广告，CPM60 美元起步、最低投入 20 万美元，定位高端渠道，直接挑战谷歌万亿美元市场，WPP 等顶级代理已率先合作。但转型风险并存：需平衡用户信任，承诺不用私聊数据；对手 Anthropi | [Link](https://longbridge.com/en/news/275993077.md) | | 领先汽车配件的沉重债务负担加剧了流动性、再融资以及业务扭转的风险 | Advance Auto Parts Inc (AAP) 正面临重大财务风险，主要由于其沉重的债务负担，这可能限制流动性和融资渠道。这种情况可能迫使更多现金流用于偿债，而非投资，从而增加对经济衰退和潜在契约违约的脆弱性。在严峻的信贷环境中， | [Link](https://longbridge.com/en/news/275997122.md) | | 伊本·阿尔·海赛姆医院全年收入为 301,281 第纳尔 | 伊本·海瑟姆医院公司 PSC (IBNH.AM)：伊本·海瑟姆医院财年税后净收入为 301,281 第纳尔；伊本·海瑟姆医院财年收入为 1210 万第纳尔 | [Link](https://longbridge.com/en/news/275996849.md) | | 新濠博亚娱乐（MLCO）在恢复季度盈利并获得创纪录的五星奖项后股价下跌 12.9% | 新濠博亚娱乐报告了 2025 年第四季度的收入为 12.9 亿美元，扭亏为盈，实现了 6064 万美元的利润，主要得益于澳门和塞浦路斯的强劲博彩表现。该公司还获得了创纪录的 19 项福布斯旅游指南五星奖，突显其在高端市场的定位。尽管财务表现 | [Link](https://longbridge.com/en/news/276002958.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.